Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

ECT2 promotes malignant phenotypes through the activation of the AKT/mTOR pathway and cisplatin resistance in cervical cancer

Cancer Gene Therapy volume 30, pages 62–73 (2023)Cite this article

Subjects

Abstract

Epithelial cell transforming sequence 2 (ECT2) is expressed at high levels in various malignancies and contributes to malignant phenotypes in cancers. However, ECT2 is still not fully understood regarding its function and carcinogenic mechanism in cervical cancer. This research indicated that ECT2 expression was elevated in cervical cancer based on bioinformatics analysis and clinical specimens. Experiments in vitro and in vivo confirmed that ECT2 knockdown could suppress the proliferation and metastasis of cervical carcinoma cells. In addition, we found that silencing ECT2 could enhance the sensitivity to cisplatin and promote cell apoptosis. Mechanistically, we observed that ECT2 knockdown could inhibit the AKT/mTOR pathway and activate apoptosis, while ECT2 overexpression induced the opposite effect. The relationship between ECT2 and AKT was further confirmed by immunoprecipitation and rescue experiments. We found that the ECT2 and AKT could interact to form a complex, and knockdown AKT could offset all of the effects induced by ECT2. Our study emphasized the key point of ECT2 in the reversal of cisplatin resistance, and ECT2 could become a potential therapeutic target in cervical cancer.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: ECT2 is highly expressed in cervical cancer.
Fig. 2: ECT2 promotes the malignant phenotype of cervical cancer cells in vitro and vivo.
Fig. 3: ECT2 regulates apoptosis of cervical cancer cells.
Fig. 4: ECT2 promotes cisplatin resistance in cervical cancer in vitro and in vivo.
Fig. 5: ECT2 promotes the malignant progression in cervical cancer through the AKT/mTOR pathway.
Fig. 6: AKT knockdown reverses the anti-apoptosis, proliferation, and AKT/mTOR pathway activating effects induced by ECT2 overexpression.

Data availability

The datasets generated during and/or analyzed during the current study are available. The RNA-sequencing data has been uploaded in Sequence Read Archive (SRA) (https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA814339).

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

    Article  Google Scholar 

  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  Google Scholar 

  3. Jedy-Agba E, Joko WY, Liu B, Buziba NG, Borok M, Korir A, et al. Trends in cervical cancer incidence in sub-Saharan Africa. Br J Cancer. 2020;123:148–54.

    Article  Google Scholar 

  4. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet 2019;393:169–82.

    Article  Google Scholar 

  5. Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. 2016;10:1885–95.

    Article  CAS  Google Scholar 

  6. Fields AP, Justilien V. The guanine nucleotide exchange factor (GEF) Ect2 is an oncogene in human cancer. Adv Enzym Regul. 2010;50:190–200.

    Article  Google Scholar 

  7. Cook DR, Rossman KL, Der CJ. Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease. Oncogene 2014;33:4021–35.

    Article  CAS  Google Scholar 

  8. Zhi T, Jiang K, Xu X, Yu T, Zhou F, Wang Y, et al. ECT2/PSMD14/PTTG1 axis promotes the proliferation of glioma through stabilizing E2F1. Neuro Oncol. 2019;21:462–73.

    Article  CAS  Google Scholar 

  9. Wang HK, Liang JF, Zheng HX, Xiao H. Expression and prognostic significance of ECT2 in invasive breast cancer. J Clin Pathol. 2018;71:442–5.

    Article  CAS  Google Scholar 

  10. Justilien V, Lewis KC, Meneses KM, Jamieson L, Murray NR, Fields AP. Protein kinase Ciota promotes UBF1-ECT2 binding on ribosomal DNA to drive rRNA synthesis and transformed growth of non-small-cell lung cancer cells. J Biol Chem. 2020;295:8214–26.

    Article  CAS  Google Scholar 

  11. Zhang H, Geng Y, Sun C, Yu J. Upregulation of ECT2 predicts adverse clinical outcomes and increases 5-fluorouracil resistance in gastric cancer patients. J Oncol. 2021;2021:2102890.

    Google Scholar 

  12. Huff LP, Decristo MJ, Trembath D, Kuan PF, Yim M, Liu J, et al. The role of Ect2 nuclear RhoGEF activity in ovarian cancer cell transformation. Genes Cancer. 2013;4:460–75.

    Article  Google Scholar 

  13. Cook DR, Kang M, Martin TD, Galanko JA, Loeza GH, Trembath DG, et al. Aberrant expression and subcellular localization of ECT2 drives colorectal cancer progression and growth. Cancer Res. 2022;82:90–104.

    Article  CAS  Google Scholar 

  14. Sun BY, Wei QQ, Liu CX, Zhang L, Luo G, Li T, et al. ECT2 promotes proliferation and metastasis of esophageal squamous cell carcinoma via the RhoA-ERK signaling pathway. Eur Rev Med Pharm Sci. 2020;24:7991–8000.

    Google Scholar 

  15. Chen J, Xia H, Zhang X, Karthik S, Pratap SV, Ooi LL, et al. ECT2 regulates the Rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma. J Hepatol. 2015;62:1287–95.

    Article  CAS  Google Scholar 

  16. Weeks A, Okolowsky N, Golbourn B, Ivanchuk S, Smith C, Rutka JT. ECT2 and RASAL2 mediate mesenchymal-amoeboid transition in human astrocytoma cells. Am J Pathol. 2012;181:662–74.

    Article  CAS  Google Scholar 

  17. Zhang ML, Lu S, Zhou L, Zheng SS. Correlation between ECT2 gene expression and methylation change of ECT2 promoter region in pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2008;7:533–8.

    CAS  Google Scholar 

  18. Chen Z, Liu J, Zhang Y. Role of epithelial cell transforming sequence 2 (ECT2) in predicting prognosis of osteosarcoma. Med Sci Monit. 2017;23:3861–8.

    Article  Google Scholar 

  19. Guo Z, Chen X, Du T, Zhu D, Lai Y, Dong W, et al. Elevated levels of epithelial cell transforming sequence 2 predicts poor prognosis for prostate cancer. Med Oncol. 2017;34:13.

    Article  Google Scholar 

  20. Gao J, Dai C, Yu X, Yin XB, Zhou F. Upregulated microRNA-194 impairs stemness of cholangiocarcinoma cells through the Rho pathway via inhibition of ECT2. J Cell Biochem. 2020;121:4239–50.

    Article  CAS  Google Scholar 

  21. Zhu L, Qin G, Ye L, Jiang LZ, Zhou TJ, Luo B, et al. Epithelial cell transforming sequence 2 expression is associated with the progression of laryngeal squamous cell carcinoma. Oncol Lett. 2019;17:5699–704.

    CAS  Google Scholar 

  22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402–8.

    Article  CAS  Google Scholar 

  23. Bahrami A, Hasanzadeh M, Hassanian SM, ShahidSales S, Ghayour-Mobarhan M, Ferns GA, et al. The potential value of the PI3K/Akt/mTOR signaling pathway for assessing prognosis in cervical cancer and as a target for therapy. J Cell Biochem. 2017;118:4163–9.

    Article  CAS  Google Scholar 

  24. Lehner CF. The pebble gene is required for cytokinesis in Drosophila. J Cell Sci. 1992;103:1021–30. Pt 4

    Article  Google Scholar 

  25. Miki T, Smith CL, Long JE, Eva A, Fleming TP. Oncogene ect2 is related to regulators of small GTP-binding proteins. Nature 1993;362:462–5.

    Article  CAS  Google Scholar 

  26. Xu D, Wang Y, Wu J, Zhang Z, Chen J, Xie M, et al. ECT2 overexpression promotes the polarization of tumor-associated macrophages in hepatocellular carcinoma via the ECT2/PLK1/PTEN pathway. Cell Death Dis. 2021;12:162.

    Article  CAS  Google Scholar 

  27. Xu J, Yao Q, Hou Y, Xu M, Liu S, Yang L, et al. MiR-223/Ect2/p21 signaling regulates osteosarcoma cell cycle progression and proliferation. Biomed Pharmacother. 2013;67:381–6.

    Article  CAS  Google Scholar 

  28. Wang X, Tong Z, Liu H. MiR-223-3p targeting epithelial cell transforming sequence 2 oncogene inhibits the activity, apoptosis, invasion and migration of MDA-MB-468 breast cancer cells. Onco Targets Ther. 2019;12:7675–84.

    Article  CAS  Google Scholar 

  29. Jin Y, Yu Y, Shao Q, Ma Y, Zhang R, Yao H, et al. Up-regulation of ECT2 is associated with poor prognosis in gastric cancer patients. Int J Clin Exp Pathol. 2014;7:8724–31.

    Google Scholar 

  30. Bai X, Yi M, Xia X, Yu S, Zheng X, Wu K. Progression and prognostic value of ECT2 in non-small-cell lung cancer and its correlation with PCNA. Cancer Manag Res. 2018;10:4039–50.

    Article  CAS  Google Scholar 

  31. Sano M, Genkai N, Yajima N, Tsuchiya N, Homma J, Tanaka R, et al. Expression level of ECT2 proto-oncogene correlates with prognosis in glioma patients. Oncol Rep. 2006;16:1093–8.

    CAS  Google Scholar 

  32. Bensen R, Brognard J. New therapeutic opportunities for the treatment of squamous cell carcinomas: a focus on novel driver kinases. Int J Mol Sci. 2021;22:2831.

    Article  Google Scholar 

  33. Mendez P, Ramirez JL. Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung. Transl Lung Cancer Res. 2013;2:101–11.

    CAS  Google Scholar 

  34. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J. 1997;11:68–76.

    Article  CAS  Google Scholar 

  35. Tatsumoto T, Xie X, Blumenthal R, Okamoto I, Miki T. Human ECT2 is an exchange factor for Rho GTPases, phosphorylated in G2/M phases, and involved in cytokinesis. J Cell Biol. 1999;147:921–8.

    Article  CAS  Google Scholar 

  36. Saito S, Liu XF, Kamijo K, Raziuddin R, Tatsumoto T, Okamoto I, et al. Deregulation and mislocalization of the cytokinesis regulator ECT2 activate the Rho signaling pathways leading to malignant transformation. J Biol Chem. 2004;279:7169–79.

    Article  CAS  Google Scholar 

  37. Xu Z, Han X, Ou D, Liu T, Li Z, Jiang G, et al. Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy. Appl Microbiol Biotechnol. 2020;104:575–87.

    Article  CAS  Google Scholar 

  38. Xu F, Na L, Li Y, Chen L. Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours. Cell Biosci. 2020;10:54.

    Article  CAS  Google Scholar 

  39. Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016;35:515–24.

    Article  CAS  Google Scholar 

  40. Pungsrinont T, Kallenbach J, Baniahmad A. Role of PI3K-AKT-mTOR pathway as a pro-survival signaling and resistance-mediating mechanism to therapy of prostate cancer. Int J Mol Sci. 2021;22:11088.

    Article  Google Scholar 

  41. Cao C, Han P, Liu L, Tang Y, Tian S, Zhang K, et al. Epithelial cell transforming factor ECT2 is an important regulator of DNA double-strand break repair and genome stability. J Biol Chem. 2021;297:101036.

    Article  CAS  Google Scholar 

  42. Tanaka I, Chakraborty A, Saulnier O, Benoit-Pilven C, Vacher S, Labiod D, et al. ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin. Nucleic Acids Res. 2020;48:2676–93.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge all participants in this study.

Funding

This research was carried out at Qilu hospital of Shangdong University and supported by the Shandong Province Key Research Project (2017CXGC1210), Natural Science Foundation Youth Project of Shandong Province (ZR2021QH044), Youth Innovation Technology Project of Higher School of Jinan (2021 GXRC027), National Natural Science Foundation of China (81902644), Natural Science Foundation of Shandong Province (ZR2019BC059 and ZR2020QH248), and Science and Technology Development Project of Shandong Province (2019GSF108126).

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China

    Xiaoli Liu, Junhua Zhang, Shuang Ju, Lu Liu, Yu Sun, Lingyu Guo, Qianwei Zhen, Sai Han, Wei Lu & Youzhong Zhang

  2. Key Laboratory of Gynecologic Oncology of Shandong Province, Jinan, China

    Xiaoli Liu, Junhua Zhang, Shuang Ju, Lu Liu, Yu Sun, Lingyu Guo, Qianwei Zhen, Sai Han, Wei Lu & Youzhong Zhang

  3. Shandong Engineering Laboratory for Urogynecology, Qilu Hospital of Shandong University, Jinan, China

    Xiaoli Liu, Junhua Zhang, Shuang Ju, Lu Liu, Yu Sun, Lingyu Guo, Qianwei Zhen, Sai Han, Wei Lu & Youzhong Zhang

Authors
  1. Xiaoli Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Junhua Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shuang Ju
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lu Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lingyu Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qianwei Zhen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sai Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wei Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Youzhong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YZ and XL participated in the conception and design of this study, and carried out the experiments. JZ, LL, YS, and WL were mainly responsible for data curation and statistical analysis. SJ, QZ, LG, and SH contributed to the preparation of drafts and the visualization of the work. All the authors participated in manuscript review and approved the final manuscript.

Corresponding author

Correspondence to Youzhong Zhang.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

Ethics approval of this research was granted by the Ethics Committee of Qilu Hospital of Shandong University. The animal study was reviewed and approved by Institute of Zoology, Shandong University.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liu, X., Zhang, J., Ju, S. et al. ECT2 promotes malignant phenotypes through the activation of the AKT/mTOR pathway and cisplatin resistance in cervical cancer. Cancer Gene Ther 30, 62–73 (2023). https://doi.org/10.1038/s41417-022-00525-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41417-022-00525-7

Search

Advanced search

Quick links